Morgan Stanley lowered the firm’s price target on Acelyrin (SLRN) to $5 from $6 and keeps an Equal Weight rating on the shares. The firm is updating its model to remove uveitis estimates following the company’s recent disclosure that the Phase 1/2 trial of izokibep did not succeed, the analyst tells investors in a research note. Following the removal of uveitis from Acelyrin model, Morgan Stanley’s base case peak sales projection decreases from about $550M to about $500M, the firm added.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SLRN:
- Acelyrin price target lowered to $13 from $15 at Wells Fargo
- ACELYRIN Faces CFO Resignation and Trial Setback
- Acelyrin Inc trading resumes
- Acelyrin announces izokibep trial did not meet primary endpoint
- Acelyrin Inc trading halted, news pending
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
